Related Articles
Phase II study of subcutaneously administered interleukin-2 in combination with medroxyprogesterone acetate and antioxidant agents as maintenance treatment in advanced cancer responders to previous chemotherapy
Immunotherapy (recombinant interleukin 2), hormone therapy (medroxyprogesterone acetate) and antioxidant agents as combined maintenance treatment of responders to previous chemotherapy
CHEMOTHERAPEUTIC TREATMENT IN UNRESECTABLE NONSMALL CELL LUNG-CANCER (NSCLC) - A FURTHER ATTEMPT TO MODULATE CISPLATIN, VINBLASTINE AND MITOMYCIN-C (PVM) SCHEDULE
CYCLOPHOSPHAMIDE, EPIDOXORUBICIN AND CARBOPLATIN AS TREATMENT FOR ADVANCED-CARCINOMA OF THE BLADDER - A PHASE-II STUDY
Measurement of endometrial thickness by transvaginal ultrasonography to predict pathological response to medroxyprogesterone acetate in patients with gradeĀ 1 endometrioid adenocarcinoma